[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"glucose-intolerance\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:glucose-intolerance":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,46,77,105,138,167,197,221,251,273,306,339],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100568659","ursodeoxycholic-acid-attenuates-statin-induced-impaired-glucose-tolerance-100568659",false,"NCT06684106","Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance","Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance: A Randomized Controlled Clinical Trial","URSTAR","Inclusion Criteria:\n\n* Age 18-75 years old.\n* LDL-C≥3.4mmol\u002Fl (130 mg\u002FdL).\n* Glycosylated hemoglobin ≤ 6.0% (42 mmol\u002Fmol).\n* Voluntarily sign informed consent.\n\nExclusion Criteria:\n\n* Previous diagnosis of diabetes or prediabetes.\n* Past or current use of hypoglycemic drugs.\n* Oral administration of statin lipid-lowering drugs within three months before enrollment.\n* Combined oral drug quantity ≥3.\n* History of ASCVD (previous myocardial infarction, ACS, stroke or TIA within 1 year, symptomatic peripheral vascular disease).\n* Active liver disease (defined as elevation of alanine aminotransferase (ALT), aspartate aminotransferase (AST) \\>2 × upper limit of normal (ULN) from any existing known liver infectious, neoplastic, or metabolic pathologic cause or unknown cause at the time of screening), Severe hepatic insufficiency and biliary obstruction.\n* Difficult to control hypertension: defined as systolic blood pressure ≥180mmHg or diastolic blood pressure ≥110mmHg despite antihypertensive therapy prior to randomization.\n* Estimated glomerular filtration rate (eGFR) ≤ 30 mL\u002Fmin\u002F1.73m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) method\n* New York Heart Association (NYHA) Class IV heart failure or a known left ventricular ejection fraction \\\u003C 25%\n* A clinically significant and drug- or ablation-resistant arrhythmia within 3 months prior to randomization\n* An acute or severe systemic infection, or any of the following diseases: hematological disorders, autoimmune disorders, malignant tumors, psychiatric patients, or other serious or unstable conditions that could impact study health status\n* Scheduled for surgery within 6 months\n* Pregnant, breastfeeding, or trying to become pregnant during the study or within 6 months of study completion\n* Subjects with alcohol or other drug addiction\n* Secondary hypercholesterolemia, such as hypothyroidism or nephrotic syndrome\n* A history of allergic reaction to any study drug or its excipients or similar chemical classes of drugs\n* A family history of homozygous familial hypercholesterolemia\n* Participants currently enrolled in another clinical trial, or who cannot adhere to 6-month follow-up\n* Any condition that the investigator considers unsuitable for participation.",true,"ALL","18 Years","75 Years",{"count":22,"type":23},128,"ESTIMATED","INTERVENTIONAL",[26],"NA","The purpose of this clinical trial is to understand whether the drug Ursodeoxycholic acid (UDCA) can prevent glucose intolerance in participants with hyperlipidemia who are taking statins. It will also assess the safety of UDCA. The primary questions it aims to answer are:\n\n* Will UDCA reduce the incidence of glucose intolerance in participants taking oral statins?\n* Will the use of UDCA decrease other adverse events in patients taking oral statins?\n\nParticipants will:\n\n* Take Atorvastatin combined with UDCA or a placebo daily for 6 months\n* Have follow-up visits on day 40, day 110, and day 180 Have their examination indicators recorded.",[29,30,31,32],"Hyperlipidemia","Ursodeoxycholic Acid","Statin Therapy","Glucose Intolerance","RECRUITING","2026-06-26",{"date":36,"type":37},"2026-06-30","ACTUAL",{"date":39,"type":37},"2024-11-25",{"date":41,"type":23},"2027-06-01",{"name":43,"class":44},"First Affiliated Hospital Xi'an Jiaotong University","OTHER",2,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":24,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100642371","metformin-withdrawal-in-metabolic-syndrome-100642371","NCT07659444","Metformin Withdrawal In Metabolic Syndrome","Effects of 14-Day Metformin Withdrawal on OGTT-Derived Insulin Sensitivity in Adults With Metabolic Syndrome: A Randomized Controlled Trial","METMS","Inclusion Criteria:\n\n* Currently treated with metformin as part of their usual medical care for at least 12 months before enrolment.\n* Diagnosis of metabolic syndrome according to established clinical criteria, based on the presence of at least three of the following components: increased waist circumference, elevated triglycerides, reduced HDL cholesterol, elevated blood pressure or antihypertensive treatment, and elevated fasting glucose or treatment for dysglycemia.\n* Stable metformin dose for at least 3 months before enrolment.\n* Willing and medically able to temporarily discontinue metformin for 14 days if assigned to the metformin discontinuation group.\n* Able and willing to undergo repeated oral glucose tolerance tests, venous catheter placement, repeated blood sampling, indirect calorimetry measurements, blood pressure measurements, and heart rate measurements.\n* willing to wear a continuous glucose monitoring device during the study period.\n* Preserved kidney function at baseline, defined as estimated glomerular filtration rate ≥60 mL\u002Fmin\u002F1.75 m² and urine albumin-to-creatinine ratio \\\u003C30 mg\u002Fg, or values considered clinically acceptable by the study physician.\n* No previous history of clinically significant diabetes-related complications, including diabetic retinopathy, diabetic foot disease, severe peripheral neuropathy, or diabetic kidney disease.\n\nExclusion Criteria:\n\n* Diagnosis of type 1 diabetes.\n* Current treatment with insulin or other glucose-lowering medications.\n* Previous history of severe hypoglycemia, diabetic ketoacidosis, hyperosmolar hyperglycemic state, or other acute diabetes-related metabolic complications.\n* Uncontrolled diabetes or clinically unsafe glycemic status at screening, defined as HbA1c above 8.0 %, fasting plasma glucose above 160 mg\u002Fdl, or any other glycemic value considered unsafe by the study physician.\n* Known allergy or intolerance to materials used in the continuous glucose monitoring device, adhesive patches, venous catheter, or study procedures.",{"count":55,"type":23},28,[26],"The goal of this clinical trial is to investigate how a short-term interruption of metformin treatment affects insulin sensitivity, glucose control, and metabolic flexibility in adults with metabolic syndrome who are taking metformin as part of their usual medical treatment. Temporary interruptions in metformin treatment may occur in real-life situations, such as missed doses, medication access problems, travel, or planned short-term discontinuation for clinical reasons. This study aims to understand whether stopping metformin for 14 days leads to rapid changes in glucose metabolism or whether the effects of previous metformin treatment may persist during a short period without the medication.\n\nThe main questions it aims to answer are:\n\nDoes stopping metformin for 14 days worsen glucose control or insulin sensitivity measured by oral glucose tolerance tests, HbA1c, and continuous glucose monitoring?\n\nDoes stopping metformin for 14 days affect metabolic flexibility, measured by indirect calorimetry during the oral glucose tolerance test?\n\nDoes stopping metformin for 14 days affect blood lipids, liver and inflammatory markers, red blood cell parameters, kidney function markers, fasting lactate levels, blood pressure, or heart rate?\n\nResearchers will compare participants who stop metformin for 14 days with participants who continue their usual metformin treatment to see whether temporary metformin discontinuation affects insulin sensitivity, glucose control, metabolic flexibility, and other cardiometabolic markers.\n\nParticipants in the metformin discontinuation group will stop taking metformin for 14 days. They will attend study visits on day 0, day 4, day 7, and day 14. At each visit, they will complete an oral glucose tolerance test, have blood samples taken, and undergo indirect calorimetry measurements before and after the glucose drink. Blood pressure and heart rate will also be measured during the test. Participants will wear a continuous glucose monitor throughout the 14-day period to track glucose levels and help detect any potentially unsafe increase in blood glucose.\n\nParticipants in the usual-treatment group will continue taking metformin as prescribed. They will attend study visits on day 0 and day 14. At each visit, they will complete an oral glucose tolerance test, have blood samples taken, and undergo indirect calorimetry, blood pressure, and heart rate measurements during the test.\n\nAt the study visits, researchers will assess glucose and insulin responses, HbA1c, continuous glucose monitoring data, metabolic flexibility, blood lipid profile, liver and inflammatory markers, red blood cell parameters, kidney function markers, fasting lactate levels, blood pressure, and heart rate.",[59,32],"Metabolic Syndrome (MetS)",[61,62,63,64,65,66],"MetS","Metabolic Syndrome","Metformin","Insulin Sensitivity","Metabolic Flexibility","OGTT","2026-06-16",{"date":69,"type":37},"2026-06-22",{"date":71,"type":37},"2026-04-05",{"date":73,"type":23},"2026-08-30",{"name":75,"class":44},"University of Castilla-La Mancha",1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":24,"phases":85,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":76},"100419090","the-impact-of-overnight-nutrition-support-on-sleep-and-circadian-rhythm-disruption-in-the-icu-100419090","NCT04737200","The Impact of Overnight Nutrition Support on Sleep and Circadian Rhythm Disruption in the ICU","Inclusion Criteria:\n\n* Adult male or non-pregnant female volunteers (age 18+)\n* Scheduled for a cardiac surgical procedure with planned post-operative admission to the ICU for \\>48 hours\n* Able and willing to give consent and comply with study procedures\n\nExclusion Criteria:\n\n* Blind, deaf or unable to speak English\n* Women who are pregnant or nursing\n* Contraindications to safe use enteral nutrition, including gastrointestinal obstruction\n* Personal history of intestinal malabsorption, gallbladder disease or pancreatitis\n* Dietary restrictions precluding enteral feeds\n* Renal and liver failure requiring dialysis or Child-Pugh score \\> 7\n* Severe deficit due to structural or anoxic brain damage\n* With skin condition that precludes wearing sensors",{"count":84,"type":23},30,[26],"The purpose of this study is to determine whether modifying the timing of nutrition support from overnight to daytime enhances sleep quality, preserves circadian rhythms, and improves overall inflammation and cardiometabolic profiles in postoperative patients in the cardiac surgical ICU on enteral nutrition.",[88,89,32],"Feeding Patterns","Sleep",[91,92,93,94,95,89],"Enteral Nutrition","Chrononutrition","Intensive Care Unit","Chronobiology","Nutrition Support","2026-05-18",{"date":98,"type":37},"2026-05-19",{"date":100,"type":37},"2022-02-08",{"date":102,"type":23},"2027-03-31",{"name":104,"class":44},"Massachusetts General Hospital",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":17,"sex":112,"minAge":113,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":24,"phases":117,"briefSummary":118,"conditions":119,"keywords":123,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":4},"100623994","effects-of-acute-sleep-deprivation-on-health-100623994","NCT07403864","Effects of Acute Sleep Deprivation on Health","Effects of Acute Partial Sleep Deprivation on Metabolic Health and Cognitive Function","Inclusion Criteria:\n\n* Age between 20-45 years.\n* Body Mass Index (BMI) between 18.5-27 kg\u002Fm².\n* No sleep-related medical conditions and good sleep quality, defined as a Pittsburgh Sleep Quality Index (PSQI) score ≤ 5.\n* Usual bedtime between 22:00-01:00, wake-up time between 06:00-09:00, with an average sleep duration of 7 to 9 hours; chronotype classified as \"definitely not evening type\" (score ≥ 42 on the Morningness-Eveningness Questionnaire), and no changes in sleep patterns over the past 3 months.\n* Without any metabolic or cardiovascular diseases, and not using medications that could affect metabolic responses.\n* No specific dietary habits, such as intermittent fasting or a ketogenic diet.\n* Maintaining a stable weight (no self-reported weight change ± 3 kg) for at least 3 months.\n* Resting blood pressure ≤ 130\u002F80 mmHg.\n* No smoking or excessive alcohol consumption.\n* Not a shift worker.\n* No international travel across time zones has occurred within the past 3 months.\n\nExclusion Criteria:\n\n* Special diets (e.g., intermittent fasting, ketogenic diet)\n* Recent injuries or contraindications to intense exercise.","MALE","20 Years","45 Years",{"count":116,"type":23},48,[26],"This study will investigate whether various types of regular exercise can provide protective effects against metabolic abnormalities induced by sleep restriction. It will examine responses related to metabolic health, cognitive function, energy expenditure, subjective feelings, and human behaviors, including physical activity and energy intake.",[32,120,121,122],"Energy Expenditure","Vascular Stiffness","Cognition",[124,125,126,127],"Partial sleep deprivation","Sleep loss","Physical inactivity","Exercise habits","NOT_YET_RECRUITING","2026-02-04",{"date":131,"type":37},"2026-02-11",{"date":133,"type":23},"2026-03-01",{"date":135,"type":23},"2027-03-01",{"name":137,"class":44},"National Taiwan Normal University",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":146,"enrollmentInfo":147,"targetDuration":4,"studyType":149,"phases":4,"briefSummary":150,"conditions":151,"keywords":154,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":76},"100142762","a-biological-atlas-of-severe-obesity-biological-tissue-collection-100142762","NCT01129297","A Biological Atlas of Severe Obesity (Biological Tissue Collection)","Influence of the Glycemic and Ponderal Status on Tissues Gene Expression (Biological Tissue Collection)","ABOS","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Indication of abdominal surgery requiring a laparotomy or laparoscopy for bariatric surgery, cholecystectomy, or parietal surgical\n* Phenotype corresponding to one of the following four cases :\n\n  1. Body Mass Index ≥ 35 kg\u002Fm2 and diabetes defined by a fasting blood glucose ≥ 7 mmol\u002Fl and\u002For ≥ to 11.1 mmol\u002Fl, 120 minutes after ingestion of glucose (hyperglycemia caused by oral route)\n  2. Body Mass Index ≥ 35 kg\u002Fm2 with intolerance glucose defined by a fasting blood glucose\\> 6 mmol\u002FL and \\\u003C7 mmol\u002Fl and\u002For\\> 7.8 mmol\u002Fl and \\\u003C11.1 mmol\u002Fl , 120 minutes after ingestion of glucose (hyperglycemia caused by oral route)\n  3. Body Mass Index ≥ 35 kg\u002Fm2 without diabetes defined by a blood glucose ≤ 6 mmol\u002FL and \u002F or ≤ 7.8 mmol\u002Fl, 120 minutes after ingestion of glucose (hyperglycemia caused by oral route)\n  4. Body Mass Index \\\u003C27 kg\u002Fm2 without diabetes defined by a blood glucose ≤ 6 mmol\u002FL and \u002F or ≤ 7.8 mmol\u002Fl, 120 minutes after ingestion of glucose (hyperglycemia caused by oral route)\n\n5)27 \\\u003CBody Mass Index \\\u003C35 kg\u002Fm2 without diabetes defined by a blood glucose ≤ 6 mmol\u002FL and \u002F or ≤ 7.8 mmol\u002Fl, 120 minutes after ingestion of glucose (hyperglycemia caused by oral route)\n\nExclusion Criteria:\n\n* unable to receive clear information\n* refusal to sign the consent form\n* pathology associated judged by the surgeon, may increase the risk of adverse events related to sampling tissue","65 Years",{"count":148,"type":23},20000,"OBSERVATIONAL","Type 2 diabetes and obesity are both multifactorial diseases resulting from gene-environment interactions. However, this interaction, as well as the specific effect of each polymorphism, remains poorly understood.\n\nWe now proposed a prospective cohort study to improve our understanding of the influence of phenotypic characteristics on gene expression in tissues involved in glucose and\u002For lipid metabolism by collecting different biological samples.",[152,32,153],"Obesity","Diabetes",[152,155,156,157],"surgery","genetic expression","collection of samples","2025-12-02",{"date":160,"type":37},"2025-12-08",{"date":162,"type":37},"2006-06-13",{"date":164,"type":23},"2027-06",{"name":166,"class":44},"University Hospital, Lille",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":174,"targetDuration":4,"studyType":149,"phases":4,"briefSummary":176,"conditions":177,"keywords":184,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":196},"100481074","rare-and-atypical-diabetes-network-100481074","NCT05544266","Rare and Atypical Diabetes Network","RADIANT","Inclusion Criteria:\n\nThe following criteria or phenotypes will be considered for suspecting \"atypical\" participants:\n\n* Type 2 diabetes diagnosed at a time when the individual was prepubertal or non-obese\n* Mendelian pattern, especially with early onset (\\\u003C18 years old)\n* Syndromic (multiple systems involved)\n* Lipodystrophic\n* Extremes of BMI\n* \"Mitochondrial\" characteristics (e.g., myopathy, hearing deficits)\n* Non-progressive\n* Rapidly progressive (\"fulminant\")\n* Low insulin requirements (\\\u003C0.5 u\u002Fkg\u002Fday)\n* Cyclical hyperglycemia with periods of remission\n* Lean persons with polycystic ovarian syndrome (PCOS)\n* History of gestational diabetes (GDM) when lean\n* Lean insulin-resistant persons\n* If islet autoantibodies and beta-cell function parameters have been measured (where \"A\" = islet cell autoantibodies, \"B\" = beta-cell function):\n\noA-B- (i.e., lacking islet autoimmunity makers and lacking beta cell function) oA-B+ with unprovoked DKA at initial presentation (i.e., lacking islet autoimmune markers, with preserved beta-cell function, but presenting with unprovoked DKA) oA-B+ of very young onset (pre-pubertal) (i.e., lacking islet autoimmune markers, with preserved beta-cell function, but very early onset T2D-like phenotype)\n\nExclusion Criteria:\n\n* Those with high likelihood of typical type 1, typical type 2, known monogenic, or other known secondary forms of diabetes\n* Refusal of consent for genetic testing\n* Islet autoantibody positive (participants who are islet autoantibody positive but present with additional atypical features i.e. syndromic, strong linear family history of diabetes may not be excluded)\n* Women who are currently pregnant",{"count":175,"type":23},2000,"RADIANT is a network of 14 clinical sites and several laboratories dedicated to the study of atypical diabetes.\n\nThe objective of this study is to define new forms of diabetes and the unique mechanisms underlying these forms of atypical diabetes. The specific aims are to:\n\n1. Identify and enroll individuals and families with undiagnosed rare and atypical forms of diabetes.\n2. Determine the etiologic basis of the metabolic disorder among individuals and families with novel forms of rare and atypical diabetes.\n3. Understand the pathophysiology of individuals and families with novel forms of rare and atypical forms of diabetes.",[178,179,32,180,181,182,183],"Diabetes Mellitus","Diabetes Mellitus Progression","Glucose Metabolism Disorders","Metabolic Disease","Endocrine; Complications","Endocrine System Diseases",[172,185,186,32],"Atypical Diabetes","Rare Diabetes","2025-08-11",{"date":189,"type":37},"2025-08-14",{"date":191,"type":37},"2020-09-30",{"date":193,"type":23},"2030-09",{"name":195,"class":44},"University of South Florida",13,{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":204,"minAge":19,"maxAge":114,"enrollmentInfo":205,"targetDuration":4,"studyType":24,"phases":206,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":76},"100363125","hepcidin-and-glucose-metabolism-100363125","NCT04008147","Hepcidin and Glucose Metabolism","The Effect of Oral Iron Supplements on Hepcidin, Insulin and Glucose Metabolism in Pregnancy","Inclusion Criteria:\n\n* week of pregnancy 24-28\n* pre-pregnancy BMI \\\u003C27.5kg\u002Fm2\n* singleton pregnancy\n* Hb \\> 8.0 g\u002Fdl\n\nWilling to either:\n\n* not take any iron supplements for 14 days (however, participants will receive a similar amount of total iron during the 4 study days that they would normally receive over 14 days) OR\n* to take the multivitamin \"Burgerstein Schwangerschaft and Stillzeit\" supplements over the 14 days (contains 30 mg iron)\n\nExclusion Criteria:\n\n* iron infusion within the past 6 months\n* severely anemic Hb\\\u003C8.0g\u002Fdl\n* acute or chronic disease\n* long-term medication\n* medical problems known to affect iron homeostasis\n* smoking","FEMALE",{"count":84,"type":23},[26],"Gestational diabetes mellitus (GDM), defined as hyperglycemia with blood glucose values above normal but below those diagnostic of DM, and iron deficiency (ID) with or without anemia (IDA) are common during pregnancy. Both disease patterns are associated with an increased risk of complications during pregnancy and at delivery and may have a variety of negative effects on different aspects of child development. Thus, GDM and ID\u002FIDA during pregnancy should be prevented.\n\nWhether iron supplementation with high oral doses acutely increases hepcidin during pregnancy, and whether this acute iron-induced increase in hepcidin decreases insulin sensitivity, is uncertain.",[209,210,32,211],"Iron Deficiency Anemia of Pregnancy","Iron Metabolism Disorders","Gestational Diabetes","2025-05-19",{"date":214,"type":37},"2025-05-22",{"date":216,"type":37},"2019-07-03",{"date":218,"type":23},"2025-12-31",{"name":220,"class":44},"Swiss Federal Institute of Technology",{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":18,"minAge":228,"maxAge":229,"enrollmentInfo":230,"targetDuration":4,"studyType":24,"phases":232,"briefSummary":233,"conditions":234,"keywords":239,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":249,"locationsCount":76},"100544247","the-acute-t-rex-timing-of-resistance-exercise-study-100544247","NCT06366399","The Acute T-Rex (Timing of Resistance Exercise) Study","Timing (AM v PM) of Acute Resistance Exercise on Glycemic Control in Older Adults: The Acute T-Rex Study","Inclusion Criteria:\n\n* Men and women, all ethnicities, aged 50-74 years\n* BMI ≥25 kg\u002Fm² and \\\u003C45 kg\u002Fm²\n* Weight stable (less than 5% change in the past 6 months)\n* Generally healthy individuals\n* Not meeting recommended activity guidelines for aerobic or resistance exercise\n\nExclusion Criteria:\n\n* Uncontrolled cardiovascular, metabolic, renal, or pulmonary disease\n* Cancer treatment in the past 5 years\n* Untreated thyroid disease or other medical conditions affecting weight or energy metabolism\n* Current use of weight loss medication or other medications likely to impact energy balance\n* Bariatric surgery or extensive bowel resection in the past 2 years\n* Current or recent history (past 2 years) of eating disorder\n* Diagnosis of insomnia, sleep apnea, or other sleep and circadian disorders\n* Non-English speaking\n* HbA1c \\>6.5%","50 Years","74 Years",{"count":231,"type":23},20,[26],"The primary aim of this study is to evaluate if a single bout of AM vs PM resistance exercise has different effects on insulin sensitivity and sleep. A randomized cross-over trial be used to compare resistance exercise at two different times of the day. Each condition will take place in a laboratory setting. Each condition will consist of exercise, overnight sleep, and oral glucose tolerance tests the following day. The AM exercise will occur \\~1.5 hours after habitual wake, and PM exercise will occur \\~11 hours after habitual wake. After a 2-6 week washout, participants will complete the other condition. The hypothesis is that PM exercise will be more beneficial than AM exercise in improving insulin sensitivity. This study could identify if there is a better time of day to perform resistance exercise to decrease risk of developing Type 2 Diabetes Mellitus.",[235,236,32,237,238,64],"Diabetes Mellitus, Type 2","Insulin Resistance","Sleep Disturbance","Overweight or Obesity",[240,241,89,242],"Resistance Exercise","Strength-training","Circadian Rhythm","2025-04-01",{"date":245,"type":37},"2025-04-03",{"date":247,"type":37},"2023-11-15",{"date":218,"type":23},{"name":250,"class":44},"University of Utah",{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":256,"acronym":4,"eligibilityCriteria":257,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":258,"targetDuration":4,"studyType":24,"phases":260,"briefSummary":261,"conditions":262,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":265,"lastUpdatePostDateStruct":266,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":271,"locationsCount":76},"100475233","the-impact-of-removal-of-exercise-on-glycemic-control-and-vascular-health-in-older-active-adults-100475233","NCT05468255","The Impact of Removal of Exercise on Glycemic Control and Vascular Health in Older Active Adults","The Impact of Removal of Exercise on Glycemic Control and Vascular Health in Older Active","Inclusion Criteria:\n\n1. 55 years and older, 18-40 years old\n2. Healthy, physically active, performing at least 90 min\u002Fweek of physical activity\n3. Free of physical limitations that may interfere with alterations in daily physical activity levels\n\nExclusion Criteria:\n\n1. Physician diagnosed HIV, hepatitis, or tuberculosis.\n2. Body weight change of greater than 5% within the previous 2 months\n3. Smoking within the previous 2 months.\n4. Taking medications that alter blood glucose levels",{"count":259,"type":23},40,[26],"The purpose of this study is to determine if an acute bout of removal of exercise reduces enothelial function and glycemic control in an active, older adult population; and whether a 3 day return to exercise restores this response. Glycemic control is the blood glucose response following the consumption of a meal. It is an indicator of insulin resistance (or type 2 diabetes) and impaired glycemic control has been suggested to lead to cardiovascular disease. Endothelial function has been shown to be improved by chronic or acute increases in physical activity. Both of these have been shown to be impaired to acute bouts of inactivity in young populations; however the impact of acute inactivity in older adults is less understood. In this proposal the investigators will examine 1)how quickly impairments in glycemic control occur to acute physical inactivity in older adults who exercise, 2) how quickly impairments in endothelial function occur to acute inactivity in older adults who exercise, and 3) whether 3 days of a return to exercise restores these responses.",[32,263,264],"Exercise","Vascular Function","2024-04-09",{"date":267,"type":37},"2024-04-10",{"date":269,"type":37},"2022-07-25",{"date":243,"type":23},{"name":272,"class":44},"Old Dominion University",{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":279,"eligibilityCriteria":280,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":281,"enrollmentInfo":282,"targetDuration":4,"studyType":24,"phases":283,"briefSummary":284,"conditions":285,"keywords":289,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":76},"100498851","sleep-and-metabolism-100498851","NCT05775627","Sleep and Metabolism","Uncovering Sleep and Circadian Mechanisms Contributing to Adverse Metabolic Health","SAM","Inclusion Criteria:\n\n* Between 18 and 40 years of age\n* Drug free\n* Established disease-free status\n\nExclusion Criteria:\n\n1. Dietary restrictions\n\n   Participants must not have dietary restrictions that could systematically bias their macronutrient intake. The following will exclude participants from enrolling in the study based on their diet:\n   * Participants who choose not to or cannot consume dairy products (milk, yogurt, cheese, ice cream)\n2. Body Composition\n\n   A body mass index (BMI) of 18.5\\\u003C \\[BMI\\] \\\u003C 25 kg\u002Fm2 and a waist circumference \\\u003C94\u002F80cm.\n3. Psychiatric\u002Fpsychological suitability\n\n   Each participant will undergo a structured interview (Mini International Neuropsychiatric Interview) with a qualified OHSU physician. This physician will supervise the administration and scoring of a Beck Depression Inventory II (BDI-II) questionnaire for each potential participant. The following will exclude individuals from participating based on their psychiatric or psychological evaluation:\n   * Individuals with evidence of psychopathology on the BDI-II, or in a structured clinical interview with the physician\n   * A history of severe psychiatric illnesses\n   * Alcoholism\n   * Drug dependency\n   * Major depression\n   * Manic depressive illness\n   * Schizophrenic disorders\n   * Panic disorder\n   * Generalized anxiety disorder\n   * Post-traumatic stress disorder\n   * Agoraphobia\n   * Claustrophobia\n   * Paranoid personality disorder\n   * Schizoid personality disorder\n   * Schizotypal personality disorder\n   * Borderline personality disorder\n   * Antisocial personality disorder.\n   * History of using antidepressant medication\n   * History of using neuroleptic medication\n   * History of using tranquilizers\n4. Drug\u002Falcohol use\n\n   Volunteers must be drug-free (including caffeine, nicotine, alcohol and herbal medications) for the entire duration of the outpatient and in-laboratory study period, with no history of drug or alcohol dependency. All participants must be:\n   * Current non-smokers, and are required to have a history of less than 5 'pack years' of smoking\n5. Medication\u002Fdrug use\n\n   Volunteers must not be taking any prescribed medications or over the counter medications, with an exception for birth control.\n6. Prior shift work\n\n   For stability of endogenous circadian rhythmicity, volunteers must have no history of the following 1 year prior to the study:\n   * Working irregular day and night hours\n   * Regular night work\n   * Rotating shift work f\n   * Not have traveled more than 1 time zone during 3 months prior to the study\n7. Chronobiologic and sleep disorders\n\n   * Hypernychthemeral sleep\u002Fwake cycle\n   * Delayed sleep phase syndrome (wake time \\> 2 hours later than desired or habitually after 10:00 AM)\n   * Advanced sleep phase syndrome (wake time \\> 2 h earlier than desired or habitually before 5:00 AM)\n   * Narcolepsy\n   * Sleep apnea (apnea index \\>15)\n   * Insomnia (sleep complaint by history or polygraphically recorded sleep efficiency \\\u003C 80%)\n   * Hypersomnia\n   * Periodic Limb Movement (PLMS) (PLMS index \\>15)\n   * Nocturnal Paroxysmal Dystonia\n   * REM-sleep behavior disorder\n   * Nocturnal Enuresis; (self-report and first night in the laboratory)\n   * Obstructive sleep apnea (apnea\u002Fhypopnea index \\>5\u002Fh as determined by at-home monitoring)\n   * The investigators will also exclude individuals with extreme chronotype using the Horne-Ostberg Morningness\u002FEveningness questionnaire (i.e., the Owl\u002FLark Questionnaire)\n8. Diseases of the Cardiovascular System\n\n   * Hypertension (systolic blood pressure \\> 140 or diastolic blood pressure \\> 90)\n   * Heart failure\n   * Cardiomyopathy\n   * Cor pulmonale\n   * Ischemic heart disease\n   * Valvular heart disease\n   * History of heart transplantation\n   * Cardiac tumors\n   * Pericardial disease\n9. Metabolic Syndrome\n\n   Following American Heart Association cutoffs, participants who have, in addition to abdominal fat (obese exclusion criteria), two or more of these factors will be excluded from the study:\n   * HDL cholesterol of less than 40 mg\u002FdL in men or less than 50 mg\u002FdL in women\n   * Systolic blood pressure \\>135 mmHg or diastolic blood pressure \\>85 mmHg\n   * Fasting blood glucose ≥ 100 mg\u002FdL\n   * Triglycerides ≥ 150 mg\u002FdL\n10. Pre-Diabetes\u002FDiabetes\n\n    For participants who have a fasting blood glucose level of ≥ 100 mg\u002FdL the investigators will measure hemoglobin A1c to exclude for diabetes (HbA1c\\>5.7%).\n11. Hypertension\n\n    An upper cut off of 140\u002F90 mmHg during an office blood pressure measure will be used as an exclusion criterion. After 5 minutes of rest in a seated position, blood pressure will be measured 3 times, taken 1 minute apart. The average will be used to confirm eligibility criteria. Current or history of beta blocker use will also be exclusionary.\n12. Disorders of the Respiratory System\n\n    * Asthma\n    * Cystic fibroses\n    * Chronic bronchitis\n    * Emphysema\n    * Airway obstruction\n    * Interstitial lung diseases\n    * Pulmonary hypertension\n    * Lung neoplasms\n    * ARDS\n13. Disorders of the Kidney and Urinary Tract\n\n    * Acute or chronic renal failure\n    * History of renal transplantation\n    * Tubulointerstitial diseases of the kidney\n    * Urinary tract obstruction\n    * Tumors of the urinary tract\n14. Infectious Diseases\n\n    * Infective endocarditis\n    * HIV infection\n    * Sexually transmitted diseases \\[e.g., syphilis (including congenital syphilis and its sequelae), gonorrhea\\],\n    * Urinary tract infection\n    * Osteomyelitis\n    * Brucellosis\n    * Toxoplasmosis,\n    * Tuberculosis\n    * Leptospirosis\n    * Lyme disease\n    * Mononucleosis\n    * Hepatitis\n    * Parasitic infections such as malaria, toxoplasmosis, giardiasis, schistosomiasis, leishmaniasis\n15. Disorders of the Gastrointestinal System\n\n    * Esophagitis\n    * Peptic ulcer and gastritis\n    * Neoplasms of the esophagus, stomach or bowel\n    * Disorders of absorption\n    * Inflammatory bowel disease\n    * Diseases of the small and large intestine\n    * Acute appendicitis\n    * Cirrhosis or neoplasms of the liver\n    * History of liver transplantation\n    * Diseases of the gallbladder and bile ducts\n    * Pancreatic disease\n16. Disorders of the Immune System, Connective Tissue and Joints\n\n    * AIDS\n    * Systemic lupus erythematosus\n    * Rheumatoid arthritis\n    * Scleroderma\n    * Ankylosing spondylitis\n    * Vasculitis\n    * Sarcoidosis\n17. Disorders of the Hematopoietic System\n\n    * Anemia\n    * Leukemia\n    * Myeloproliferative diseases\n    * History of bone marrow transplantation\n18. Neoplastic Diseases\n\n    * Lymphoma\n    * Carcinoma\n    * Melanoma\n    * Any other neoplastic diseases\n19. Endocrine and Metabolic Diseases\n\n    * Thyroid disease\n    * Addison's Disease\n    * Cushing's Syndrome\n    * Aldosteronism\n    * Hypoaldosteronism\n    * Pheochromocytoma\n    * Disorders of sexual differentiation that require hormone supplementation that may alter body weight\n    * Disorders of neuroendocrine regulation\n    * Diseases of the anterior pituitary and hypothalamus\n    * Hemochromatosis porphyria\n    * Wilson's Disease\n    * Glycogen storage diseases\n    * Diseases of the parathyroid gland\n    * Metabolic bone disease\n    * Disorders of phosphorus or magnesium metabolism\n    * Paget's Disease\n20. Neurologic Disorders\n\n    * Epilepsy and disorders of consciousness\n    * Dementia\n    * Amnesic disorders\n    * Neoplastic diseases of the central nervous system\n    * Demyelinating diseases\n    * Parkinson's Disease\n    * Muscular dystrophy\n    * Myasthenia gravis\n    * Periodic paralysis\n    * Dermatomyositis\n    * Polymyositis\n    * Infections of the nervous system\n    * Stroke\n    * History of transient ischemic attacks\n    * Hydrocephalus\n    * Tumors of the pituitary gland\n    * Pinealoma\n    * Intervertebral disc disease\n    * Ataxia\n    * Gilles de la Tourette Syndrome\n    * Huntington's Disease\n    * Tardive dyskinesia\n    * History of recurrent migraine headaches\n    * Neuromuscular disease.\n21. Subjects must not be currently participating in another research study that would influence their safe participation in our study. Subjects must not be participating in a research study in which they do the following:\n\n    * Ingest experimental medication\n    * Give blood samples","40 Years",{"count":231,"type":23},[26],"The goal of this study is to uncover sleep and circadian mechanisms contributing to adverse metabolic health. The protocol is a 21 day (7 outpatient days, 14 inpatient days) mechanistic randomized-crossover study designed to identify the impact of chronic sleep restriction and circadian timing, independently and in combination on energy metabolism and identify the independent and combined effects on glucose tolerance.",[286,152,32,287,288],"Sleep Deprivation","Weight Gain","Food Selection",[290,291,292,293,294,295,296],"sleep restriction","obesity","glucose intolerance","weight gain","circadian timing","ad libitum","food selection","2024-04-02",{"date":299,"type":37},"2024-04-03",{"date":301,"type":37},"2023-12-01",{"date":303,"type":23},"2027-06-30",{"name":305,"class":44},"Oregon Health and Science University",{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":312,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":18,"minAge":314,"maxAge":315,"enrollmentInfo":316,"targetDuration":4,"studyType":24,"phases":318,"briefSummary":319,"conditions":320,"keywords":324,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":76},"100434955","dietary-strategies-for-remission-of-type-2-diabetes-100434955","NCT04943926","Dietary Strategies for Remission of Type 2 Diabetes","Dietary Strategies for Remission of Type 2 Diabetes - a Randomized Controlled Trial (CARBCOUNT)","CARBCOUNT","Inclusion Criteria:\n\n* HbA1c ≥48 mmol\u002Fmol (with or without medical treatment)\n* Less than 10 years since the diagnosis of T2D\n* BMI ≥27 kg\u002Fm2 (≥25 kg\u002Fm2 for Asians)\n\nExclusion Criteria:\n\n* Treatment with insulin \\>25 IU\n* HbA1c concentration of 12% or more (≥108 mmol\u002Fmol)\n* Insulin to C-peptide ratio \\\u003C0.8 (indicative of insulin deficiency)\n* Myocardial infarction within the previous 6 months, and severe or unstable heart failure or other severe diseases including cancer, psychiatric\u002Feating disorders, severe depression and substance abuse","24 Years","70 Years",{"count":317,"type":23},600,[26],"In this project, the investigators will perform a multicenter randomised controlled trial to determine whether advice to consume a moderate, whole food-based low-carbohydrate high-fat (LCHF) ad libitum diet (CarbCount program) can produce and maintain equal remission rates of type 2 diabetes (T2D) as a nutritionally complete very-low-calorie formula diet followed by a energy-restrictive (i.e., calorie counting) diet (DiRECT principles). Within the principles of each approach, the dietary goals and change will be adjusted according to individual needs\u002Fcapabilities conducive to long-term adherence. Furthermore, the investigators aim to determine whether the rate of diet-induced remission is reflected in\u002Fcan be predicted by baseline or diet-induced changes in glucose variability (e.g., time-in-range measured by continuous glucose monitoring) and other factors such as anthropometric changes and genetic susceptibility. Each center will also conduct locally-lead standalone mechanistic research, including analyses of intra-abdominal\u002Fhepatic fat accumulation, adipose tissue biopsies and\u002For measurements of energy metabolism. Additionally, changes in medication use, nutritional status, cardiovascular disease risk, as well as adverse events, will be monitored.",[235,321,322,32,236,323],"Overweight and Obesity","Hypertension","Dyslipidemia Associated With Type II Diabetes Mellitus",[325,326,327,328,329],"Low-carbohydrate high-fat diet","Energy restricted diet","Lifestyle change","Ketogenic diet","Total meal replacement","2022-07-04",{"date":332,"type":37},"2022-07-08",{"date":334,"type":37},"2022-01-04",{"date":336,"type":23},"2040-12-31",{"name":338,"class":44},"University of Bergen",{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":11,"sex":18,"minAge":345,"maxAge":346,"enrollmentInfo":347,"targetDuration":4,"studyType":149,"phases":4,"briefSummary":349,"conditions":350,"keywords":4,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":4},"100448629","mal-ed-metabolic-a-follow-up-of-chronic-disease-at-puberty-100448629","NCT05121935","MAL-ED Metabolic: A Follow-Up of Chronic Disease at Puberty","Inclusion Criteria:\n\n* Participated in original MAL-ED cohort\n\nExclusion Criteria:\n\n* Did not participate in original MAL-ED cohort","9 Years","17 Years",{"count":348,"type":23},254,"The concept that the roots of cardiometabolic disease start in early life was established by Dr. David Barker, who documented relationships between low birthweight (as a marker for challenges during gestation) and later cardiovascular disease (CVD). Later work has suggested that post-natal challenges (similar to prenatal ones) may also exhibit links to later cardiometabolic disease, with the strongest links appearing to be between low weight in early childhood and later hypertension and high waist circumference (WC). However, assessments for the relationship between early childhood challenges and insulin resistance and glucose regulation have been lacking and long-term cohort studies are few. In this project, we aim to assess children initially followed as part of The Etiology, Risk Factors, and Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health (MAL-ED) study, where they received frequent measures of anthropometry and laboratory assessments for intestinal pathogens. These children are now of peri-pubertal age--a time period associated with metabolic shifts. We will assess for glucose dysregulation and findings associated with the metabolic syndrome, and we will analyze potential associations between current chronic disease risk findings with early life poor growth and intestinal pathogen carriage rate. As such, we hope to uncover potential targets in early life health to reduce later chronic disease risk.",[351,352,62,32],"Growth Failure","Intestinal Infection","2021-11-03",{"date":355,"type":37},"2021-11-16",{"date":357,"type":23},"2022-02-01",{"date":359,"type":23},"2031-02-01",{"name":361,"class":44},"University of Virginia"]